NCT06435507View on ClinicalTrials.gov

Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

January 30, 2024

Study Completion Date

May 28, 2024

Conditions
Herpes Simplex Virus
Interventions
DRUG

IM-250 (50 mg)

Single dose

DRUG

IM-250 (100 mg)

Single dose

DRUG

IM-250 (200 mg)

Single dose

DRUG

IM-250 (400 mg)

Single dose

Trial Locations (1)

Unknown

University Hospital Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg

All Listed Sponsors
lead

Innovative Molecules GmbH

INDUSTRY